


3RD INTERNATIONAL HIV/VIRAL  
HEPATITIS CO-INFECTION MEETING

**HIV / VIRAL HEPATITIS:**  
**IMPROVING DIAGNOSIS, ANTIVIRAL  
THERAPY AND ACCESS**



The **3<sup>rd</sup> International HIV/Viral Hepatitis Co-Infection Meeting**, hosted by the International AIDS Society (IAS), takes place just prior to the 21<sup>st</sup> International AIDS Conference (AIDS 2016) on 17 July, 2016 in Durban, South Africa.

The recent development of highly effective antiviral therapy for HBV and HCV provides the opportunity to counter the rising burden of chronic liver disease among people living with HIV. Global antiretroviral therapy scale-up should limit HBV-related liver disease, through dual antiviral activity. Furthermore, development of antiretroviral therapy delivery infrastructure should enhance implementation of interferon-free DAA regimens for HCV once available. The focus of the meeting is to identify challenges and opportunities for increasing the diagnosis and treatment of viral hepatitis in people living with HIV, particularly in low and middle-income settings.

The 3<sup>rd</sup> International HIV/Viral Hepatitis Co-Infection Meeting fills a void in the landscape of meetings providing a unique opportunity for industry, academic, community and governmental stakeholders to interact and develop constructive solutions together that can support equitable access to modern therapeutics while maintaining sustainable innovation. The conference provides research-based evidence to demonstrate the value of these curative therapies and engages policy makers towards creating an environment that supports their wider therapeutic access nationally and internationally.

## MEETING OBJECTIVES

- *To review the latest therapeutic developments in viral hepatitis B and C*
- *To identify challenges and successes in scaling up diagnosis, screening, antiviral treatment and prevention of viral hepatitis in HIV co-infected persons*
- *To identify how to optimize outcomes and costs to achieve sustainable and equitable access to these therapies globally*
- *To learn from successful models, such as novel voluntary licensing agreements and map a path toward scaling up of viral hepatitis treatment programmes in low-, middle- and high-income settings*
- *To advance the agenda for viral hepatitis eradication by assembling key stakeholders for a face-to-face discussion of major barriers and solutions.*

# PROGRAMME SCHEDULE

| TIME                 | SUBJECT   | SPEAKER   |
|----------------------|---|---|
| 08:00 – 08:30        | Registration  |   |
| 08:30 – 08:45        | <b>Welcome and introduction</b>   | Meeting Co-Chair: <b>Wendy Spearman</b> ,<br>University of Cape Town  |
| 08:45 – 11:00        | <b>Hepatitis B topics</b>   | Co-Chairs: <b>Lynne Mofenson</b> , Elizabeth Glaser<br>Pediatric AIDS Foundation<br><b>Tongai Maponga</b> , Stellenbosch<br>University  |
| 08:45 – 09:15        | HBV-HIV co-infection: Epidemiology,<br>vaccine and treatment coverage                           | <b>Mark Sonderup</b> , University of Cape Town  |
| 09:15 – 09:45        | PMTCT for HBV   | <b>Monique Andersson</b> , Stellenbosch University  |
| 09:45 – 10:15        | HBV resistance and escape mutants   | <b>Anders Boyd</b> , INSERM   |
| 10:15 – 10:45        | Curing HBV: How close are we?   | <b>Patrick Kennedy</b> , Barts and The London School<br>of Medicine   |
| 10:45 – 11:00        | Panel discussion  | Session speakers  |
| <b>11:00 – 11:30</b> | <b>Break &amp; poster viewing (HBV epidemiology and outcomes)</b>                               |   |
| 11:30 – 12:30        | <b>Clinical case discussions: Challenges in HBV<br/>management in resource-limited settings</b> | Co-Chairs: <b>Mauro Schechter</b> , Universidade<br>Federal do Rio de Janeiro<br><b>Motswedi Anderson</b> , Botswana<br>Harvard AIDS Institute<br>Partnership Research Laboratory |
| 11:30 – 12:00        | HCC screening and management  | <b>Patrick Kennedy</b> , Barts and The London School<br>of Medicine   |
| 12:00 – 12:30        | Children and adolescents  | <b>Tammy Meyers</b> , Chinese University of Hong<br>Kong; University of the Witwatersrand   |
| <b>12:30 – 13:30</b> | <b>Lunch &amp; poster viewing</b>   | <b>HCV epidemiology and natural history - 12:30 - 13:00</b><br><b>HCV testing, monitoring and management - 13:00 - 13:30</b>  |
| 13:30 – 15:30        | <b>Hepatitis C topics</b>   |   |
| 13:30 – 14:20        | <b>HCV epidemiology: The knowns and the<br/>unknowns</b>  | Co-Chairs: <b>Julie Bruneau</b> , Université de<br>Montréal<br><b>Maria Prins</b> , University of<br>Amsterdam  |
| 13:30 – 13:50        | HCV in PWID in Africa: A hidden epidemic  | <b>Niklas Luhmann</b> , Médecins du Monde   |

# PROGRAMME SCHEDULE

| TIME   | SUBJECT   | SPEAKER  |
|--|---|--|
| 13:50 – 14:20  | <i>Current trends worldwide: Implications for elimination</i>                   | <b>Margaret Hellard</b> , Burnet Institute   |
| 14:20 – 15:30  | <b>HCV treatment update: A moving target</b>                                    | Co-Chairs: <b>Greg Perry</b> , Medicines Patent Pool<br><b>Margaret Hellard</b> , Burnet Institute   |
| 14:20 – 14:40  | <i>Role of resistance and resistance testing for managing HCV</i>               | <b>Jürgen Rockstroh</b> , University of Bonn   |
| 14:40 – 15:00  | <i>Is a pan-genotypic therapy ready for prime time?</i>                         | <b>Marina Klein</b> , McGill University;<br>CIHR Canadian HIV Trials Network (CTN)   |
| 15:00 – 15:20  | <i>Financing and the scale up of HCV treatments: Entry of generics</i>          | <b>Sunil Solomon</b> , Johns Hopkins University School of Medicine   |
| 15:20 – 15:30  | <i>Medicines Patent Pool</i>  | <b>Greg Perry</b> , Medicines Patent Pool  |
| <b>15:30 – 16:00 Break &amp; poster viewing (HCV treatment access)</b> |   |  |
| 16:00 – 17:15  | <b>New tools, new technologies</b>  | Co-Chairs: <b>Anja De Weggeheire</b> , Institute of Tropical Medicine<br><b>Jürgen Rockstroh</b> , University of Bonn  |
| 16:00 – 16:20  | <i>Screening for viral hepatitis: Diagnostics (HBV and HCV)</i>                 | <b>Diana Hardie</b> , University of Cape Town  |
| 16:20 – 16:40  | <i>Screening for viral hepatitis: Liver disease</i>                             | <b>Wendy Spearman</b> , University of Cape Town  |
| 16:40 – 17:00  | <i>WHO Diagnostic Guidelines</i>  | <b>Philippa Easterbrook</b> , WHO  |
| 17:00 – 17:15  | <i>Panel discussion</i>   | Session speakers   |
| 17:15 – 18:15  | <b>Panel discussion – Accessing antivirals: Overcoming remaining challenges</b> | Co-Chairs: <b>Isabelle Andrieux-Meyer</b> , MSF<br><b>Tracy Swan</b> , MSF Access Campaign   |
| 17:15 – 17:25  | <i>Opening overview and community perspective</i>                               | <b>Isabelle Andrieux-Meyer</b> , MSF   |
| 17:25 – 18:15  | <i>Panel discussion</i>   | <b>Andrew Scheibe</b> , University of Cape Town<br><b>Giten Khwairakpam</b> , TREAT Asia<br><b>Mark Sonderup</b> , University of Cape Town<br><b>Nalinikanta Rajkumar</b> , Community Network for Empowerment (CoNE)<br><b>Nelson Medeiros</b> , OUT Wellbeing |
| 18:15 – 18:30  | <b>Closing remarks</b>  | Meeting Co-Chair: <b>Marina Klein</b> , McGill University;<br>CIHR Canadian HIV Trials Network (CTN)   |

# ABSTRACTS SELECTED FOR POSTER PRESENTATION

## HBV EPIDEMIOLOGY AND OUTCOMES (AUTHORS TO PRESENT 11:00 - 11:30)

### **Higher mortality in HIV-HBV co-infected persons with elevated HBV replication in the Temprano Trial**

M.G. Kouamé, R. Moh, A. Boyd, A. Badjé, D. Gabillard, J.B. N'takpé, S. Maylin, S.P. Eholié, X. Anglaret, C. Danel

### **The effect of HIV infection on the age at presentation of HBV-driven hepatocellular carcinoma in South Africa**

T. Maponga, H. Vermeulen, B. Robertson, S. Burmeister, W. Preiser, M. Kew, M. Andersson

### **Impact of antiretroviral therapy on liver stiffness among Zambian adults with HIV-HBV co-infection and HIV mono-infection**

M. Vinikoor, E. Sinkala, R. Chilengi, L. Mulenga, B. Chi, Z. Zyambo, C. Hoffmann, M.-A. Davies, M. Egger, G. Wandeler

### **Improved liver fibrosis scores in treated HBV/HIV co-infected patients in South Africa despite persistent immune dysregulation**

T. Maponga, M. Andersson, J. Taaijaard, C.J. Van Rensburg, W. Preiser, R. Glashoff

### **Response to Truvada based cART in HIV/HBV co-infected patients in Botswana**

M. Anderson, S. Gaseitsiwe, S. Moyo, K.P. Thami, T. Mohammed, D. Setlhare, T.K. Sebulaya, E.A. Powell, J. Makhema, J.T. Blackard, R. Marlink, M. Essex, R.M. Musonda

## HCV EPIDEMIOLOGY AND NATURAL HISTORY (AUTHORS TO PRESENT 12:30 - 13:00)

### **Effect of the timing of hepatitis C virus infection relative to HIV seroconversion on CD4 T cell and HIV RNA evolution among HIV-positive MSM**

D. van Santen, J. van der Helm, G. Touloumi, N. Pantazis, R. Muga, B. Bartmeyer, J. Gill, E. Sanders, A. Kelleher, R. Zangerle, C. Béguelin, K. Porter, M. Prins, R. Geskus

### **Hepatitis C prevalence, viral diversity and severity of liver disease in HIV patients in Phnom Penh, Cambodia**

A. De Wegheleire, S. An, I. De Baetselier, S. Teav, V. So, S. Sea, S. Ros, S. Thai, S. Francque, L. Lynen

### **Extremely low hepatitis C antibody prevalence among high-risk, HIV-positive and HIV-negative men who have sex with men and transgender women from community-based organizations in Thailand**

V. Sapsirisavat, A. Avihingsanon, D. Trachunthong, S. Kerr, J. Jantarapakde, S. Pengnonyang, S. Jitjang, R. Janamnuaysook, P. Mingkwanrungrueng, J. Ohata, A. Sohn, A. Katz, N. Phanuphak

## HCV TESTING, MONITORING AND MANAGEMENT (AUTHORS TO PRESENT 13:00 - 13:30)

### **Telaprevir containing triple therapy in acute HCV co-infection: the CHAT study**

C. Boesecke, G.J. Singh, S. Scholten, T. Lutz, A. Baumgarten, S. Schneeweiss, A. Trein, M. Rausch, P. Ingiliz, J.K. Rockstroh, M. Nelson

### **Development and validation of a risk score to assist testing for acute HCV infection in HIV-infected MSM**

A.M. Newsom, I.G. Stolte, J.T.M. van der Meer, J. Schinkel, M. van der Valk, J.W. Vanhommerig, A. Buvé, M. Danta, A. Hogewoning, M. Prins

### **Non-invasive serum markers suggest benefit for early ART initiation on liver fibrosis progression within the START study**

G. Matthews, J. Neuhaus, J. Rockstroh, L. Peters, F. Gordin, A. Arenas-Pinto, C. Emerson, K. Marks, J. Hidalgo, R. Castro, C. Stephan, N. Kumarasamy, S. Emery

### **Ledipasivir/sofosbuvir for 6 weeks in HIV-infected patients with acute HCV infection**

M. Nelson, S. Bhagani, R.H. Hyland, C. Yun, M. Mertens, A. Jackson, W. Zheng, D.M. Brainard, J.G. Mchutchinson, P. Ingiliz, T. Lutz, J.K. Rockstroh

### **SOF/VEL for 12 weeks results in high SVR12 rates in subjects with negative predictors of response to treatment: an integrated analysis of efficacy from the ASTRAL-1, ASTRAL-2, and ASTRAL-3 studies**

M. Sulkowski, K. Agarwal, K. Patel, D. Samuel, M. Bourlière, Z. Younes, T. Morgan, S. Strasser, B. Leggett, S. Naik, B. Collins, M. Natha, L. Liu, X. Ding, J. McNally, A. Osinusi, D.M. Brainard, J. McHutchinson, N. Afzhal, I. Walker, N. Brau

### **Retreatment of HCV/HIV co-infected patients who failed 12 weeks of LDV/SOF**

A. Luetkemeyer, C. Cooper, S. Naggie, M. Saag, D. Dieterich, M. Sulkowski, S. Naik, M. Natha, J. Yang, L. Stamm, H. Dvory-Sobol, I. Walker, J. McHutchinson

## HCV TREATMENT ACCESS (AUTHORS TO PRESENT 15:30 - 16:00)

### **Treatment scale-up in Australia to achieve global hepatitis C virus incidence and mortality elimination targets: a cost-effectiveness model**

M. Hellard, N. Scott, E. McBryde, A. Thompson, J. Doyle

### **Rapidly falling costs for new hepatitis C direct-acting antivirals (DAAs): potential for universal access**

D. Gotham, M. Barber, J. Fortunak, A. Pozniak, A. Hill

### **Exposure to various combinations of harm reduction strategies in relation to HIV and HCV incidences among PWID in Montreal, Canada**

J. Bruneau, D. Jutras-Aswad, G. Zang, É. Roy

### **Community engagement in universal access to DAA hepatitis C treatment: the Portuguese case**

D. Simões, R. Freitas, B. dos Santos, R. Furtos, L. Mendão

### **Increasing HCV access through clinical education: medical provider knowledge and practice change intentions**

N. Harris, T. Wilder, K. McKinnon, S.H. Kim, A. Urbina

## CO-CHAIRS

### **Marina Klein**

McGill University;  
CIHR Canadian HIV Trials Network (CTN)  
Montreal, Canada

### **Wendy Spearman**

Cape Town University  
Cape Town, South Africa

## OTHER ORGANIZING COMITTEE MEMBERS

### **Monique Andersson**

Convener of HBV prevention and management theme  
Stellenbosch University, Faculty of Health Sciences  
Stellenbosch, South Africa

### **Isabelle Andrieux-Meyer**

Co-convener of HCV and HBV access theme  
Médecins Sans Frontières (MSF)  
Geneva, Switzerland

### **Anchalee Avihingsanon**

Co-convener of Epidemiology and disease burden theme  
HIV-NAT  
Bangkok, Thailand

### **Sanjay Bhagani**

Co-convener of complex issues in HCV and HBV theme  
Royal Free Hospital  
London, UK

### **Christoph Boesecke**

EACS Liaison  
University of Bonn  
Bonn, Germany

### **Laurent Castera**

EASL Liaison  
Hôpital Beaujon  
Paris, France

### **Curtis Cooper**

Co-convener of HCV therapeutic development theme  
The University of Ottawa;  
CIHR Canadian HIV Trials Network (CTN)  
Ottawa, Canada

### **Greg Dore**

Convener of treatment in special populations theme  
Kirby Institute, University of New South Wales  
Sydney, Australia

### **Jordan Feld**

Convener of HBV therapeutic development  
University of Toronto  
Toronto, Canada

### **Karine Lacombe**

Convener of epidemiology and disease burden theme  
Hôpital Saint-Antoine  
Paris, France

### **Gail Matthews**

Convener of complex issues in HCV and HBV theme  
Kirby Institute, University of New South Wales  
Sydney, Australia

### **Sébastien Morin**

Point of contact for coordination with the IAS and AIDS2016  
International AIDS Society  
Geneva, Switzerland

### **Marion Peters**

Co-convener of HBV therapeutic development theme  
University of California  
San Francisco, USA

### **Jürgen Rockstroh**

Convener of treatment in special populations theme  
University of Bonn  
Bonn, Germany

### **Mark Sulkowski**

Convener of HCV therapeutic development theme  
Viral Hepatitis Center, John Hopkins  
Baltimore, USA

### **Tracy Swan**

Convener of HCV and HBV access theme  
Médecins Sans Frontières (MSF) Access Campaign  
New York, USA